Three-Year Clinical Outcomes of Everolimus-Eluting Stents From the Post-Marketing Surveillance Study of Cobalt-Chromium Everolimus-Eluting Stent (XIENCE V/PROMUS) in Japan
-
- Aoki Jiro
- Division of Cardiology, Mitsui Memorial Hospital
-
- Kozuma Ken
- Department of Cardiology, Teikyo University Hospital
-
- Awata Masaki
- Department of Advanced Cardiovascular Therapeutics, Osaka University Graduate School of Medicine
-
- Nanasato Mamoru
- Cardiovascular Center, Nagoya Daini Red Cross Hospital
-
- Shiode Nobuo
- Division of Cardiology, Akane Foundation Tsuchiya General Hospital
-
- Tanabe Kengo
- Division of Cardiology, Mitsui Memorial Hospital
-
- Yamaguchi Junichi
- Department of Cardiology, Tokyo Women’s Medical University
-
- Kusano Hajime
- Abbott Vascular
-
- Nie Hong
- Abbott Vascular
-
- Kimura Takeshi
- Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine
この論文をさがす
抄録
Background:The Cobalt-Chromium Everolimus-Eluting Stent (CoCr-EES) Post-marketing Surveillance (PMS) is a prospective multicenter registry designed to evaluate the safety and efficacy of XIENCE V/PROMUS everolimus-eluting stents in routine clinical practice at 47 centers representative of the clinical environment in Japan.Methods and Results:We enrolled 2,010 consecutive patients (2,649 lesions) who underwent PCI using CoCr-EES. Clinical outcomes were evaluated for up to 3 years. Clinical follow-up was available in 1,930 patients (96%) at 3 years. Major adverse cardiovascular events (MACE) occurred in 6.8% of patients, including cardiac death (1.7%), myocardial infarction (1.5%), and clinically driven target lesion revascularization (CD-TLR, 4.2%). Late CD-TLR rate was 0.8% from 1 to 2 years, and 0.5% from 2 to 3 years. Definite or probable stent thrombosis occurred in 7 patients (0.3%) up to 1 year. There was no very late definite or probable stent thrombosis from 1 to 3 years. Significant independent predictors for MACE were hemodialysis, prior coronary intervention, triple-vessel coronary artery disease, and age >70 years.Conclusions:Three-year clinical outcomes from the CoCr-EES PMS demonstrated a low incidence of clinical events. There was no major concern about very late stent thrombosis or late catch-up phenomenon in patients treated with EES in routine clinical practice in Japan. (Circ J 2016; 80: 906–912)
収録刊行物
-
- Circulation Journal
-
Circulation Journal 80 (4), 906-912, 2016
一般社団法人 日本循環器学会
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1390282680085773184
-
- NII論文ID
- 130005139584
-
- NII書誌ID
- AA11591968
-
- ISSN
- 13474820
- 13469843
-
- NDL書誌ID
- 027203087
-
- PubMed
- 26821583
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可